Notably, only T84.66-LCHA-4-1BBL consistently demonstrated significant tumor growth control across the performed experiments as a combination partner with CEA-TCB when compared with CEA-TCB monotherapy (Figure 4C–E). This evidence concerns the gene CEACAM5 and neoplasm.